These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. Musat D; Sherrid MV Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():9-17. PubMed ID: 17162264 [TBL] [Abstract][Full Text] [Related]
5. [Drug treatment for hypertrophic cardiomyopathy]. Gibelin P Presse Med; 2009 Jun; 38(6):1001-4. PubMed ID: 19446431 [TBL] [Abstract][Full Text] [Related]
6. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Kajimoto K; Imai T; Minami Y; Kasanuki H Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829 [TBL] [Abstract][Full Text] [Related]
7. Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy. Nagueh SF; Buergler JM; Quinones MA; Spencer WH; Lawrie GM J Am Coll Cardiol; 2007 Aug; 50(8):795-8. PubMed ID: 17707185 [TBL] [Abstract][Full Text] [Related]
8. Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. Elesber A; Nishimura RA; Rihal CS; Ommen SR; Schaff HV; Holmes DR Am J Cardiol; 2008 Feb; 101(4):516-20. PubMed ID: 18312769 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms. Kaltenbach M; Hopf R J Mol Cell Cardiol; 1985 Jul; 17 Suppl 2():59-68. PubMed ID: 4040978 [TBL] [Abstract][Full Text] [Related]
10. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. Verlinden NJ; Coons JC Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556 [TBL] [Abstract][Full Text] [Related]
11. [Hypertrophic cardiomyopathy: place and limitations of medical therapy]. Desnos M; Hagège A; Guérot C Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):573-5. PubMed ID: 7487302 [TBL] [Abstract][Full Text] [Related]
12. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Melacini P; Maron BJ; Bobbo F; Basso C; Tokajuk B; Zucchetto M; Thiene G; Iliceto S Heart; 2007 Jun; 93(6):708-10. PubMed ID: 17502652 [TBL] [Abstract][Full Text] [Related]
13. Extended myectomy for hypertrophic obstructive cardiomyopathy after failure or contraindication of septal ablation or with combined surgical procedures. Dörge H; Schmitto JD; Liakopoulos OJ; Walther S; Schöndube FA Thorac Cardiovasc Surg; 2004 Dec; 52(6):344-8. PubMed ID: 15573275 [TBL] [Abstract][Full Text] [Related]
14. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Woo A; Williams WG; Choi R; Wigle ED; Rozenblyum E; Fedwick K; Siu S; Ralph-Edwards A; Rakowski H Circulation; 2005 Apr; 111(16):2033-41. PubMed ID: 15824202 [TBL] [Abstract][Full Text] [Related]